The complex molecular landscape in NSCLC comprises genetic alterations in a wide range of genes coding mainly for key and druggable components of the receptor tyrosine kinase (RTK)-RAS-mitogen-activated protein kinase (MAPK) axis. The gene discussed is WNK2; the disease is non-small cell lung carcinoma.